7月7日 - ** 生物技术公司Revolution Medicines（RVMD.O）的股价在盘前交易中上涨1.3%，至192.42美元
** 欧洲药品管理局表示，其人类药品专家委员会已开始对Revolution Medicines用于治疗转移性胰腺癌的试验性药物daraxonrasib进行分阶段审查
** 分阶段审查使欧盟监管机构能够随着数据的陆续提交分阶段进行评估，这有望缩短整体审查时间
** 欧洲药品管理局表示，该决定基于一项晚期临床试验数据，该试验比较了达拉克松拉西布与化疗在先前治疗后胰腺癌已转移并恶化的患者中的疗效
** RVMD此前曾表示 (link)，在一项晚期研究中，达拉克松拉西布使总生存期几乎翻倍，中位生存期为13.2个月，而化疗组为6.7个月
** 欧洲药品管理局表示，这些患者的治疗选择有限，且在既往治疗导致病情恶化后，预期寿命约为六个月
** 截至上一交易日收盘，RVMD今年以来累计上涨138.5%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.